GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Inventiva SA (NAS:IVA) » Definitions » Cash And Cash Equivalents

Inventiva (Inventiva) Cash And Cash Equivalents : $29.35 Mil (As of Dec. 2023)


View and export this data going back to 2020. Start your Free Trial

What is Inventiva Cash And Cash Equivalents?

Inventiva's quarterly cash and cash equivalents declined from Dec. 2022 ($91.88 Mil) to Jun. 2023 ($33.85 Mil) but then stayed the same from Jun. 2023 ($33.85 Mil) to Dec. 2023 ($29.35 Mil).

Inventiva's annual cash and cash equivalents declined from Dec. 2021 ($97.80 Mil) to Dec. 2022 ($91.88 Mil) and declined from Dec. 2022 ($91.88 Mil) to Dec. 2023 ($29.35 Mil).

Inventiva Cash And Cash Equivalents Historical Data

The historical data trend for Inventiva's Cash And Cash Equivalents can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Inventiva Cash And Cash Equivalents Chart

Inventiva Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cash And Cash Equivalents
Get a 7-Day Free Trial Premium Member Only Premium Member Only 39.82 128.57 97.80 91.88 29.35

Inventiva Semi-Annual Data
Dec13 Dec14 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Cash And Cash Equivalents Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 97.80 80.77 91.88 33.85 29.35

Inventiva Cash And Cash Equivalents Calculation

Cash and cash equivalents are the most liquid assets on the balance sheet. Cash equivalents are assets that are readily convertible into cash, such as money market holdings, short-term government bonds or Treasury bills, marketable securities and commercial paper.

Inventiva  (NAS:IVA) Cash And Cash Equivalents Explanation

A high number means either:

1) The company has competitive advantage generating lots of cash

2) Just sold a business or bonds (not necessarily good)

A low stockpile of cash usually means poor to mediocre economics.

There are 3 ways to create large cash reserve.

1) Sell new bonds or equity to public

2) Sell business or asset

3) It has an ongoing business generating more cash than it burns (usually means durable competitive advantage)

When a company is suffering a short term problem, Buffett looks at cash or marketable securities to see whether it has the financial strength to ride it out.

Important: Lots of cash and marketable securities + little debt = good chance that the business will sail on through tough times.

Test to see what is creating cash by looking at past 7 yrs of balance sheets. This will reveal how the cash was created.

Be Aware

Depreciation estimates make the calculation of net income susceptible to management's accounting choices. These choices can be either overly aggressive or overly conservative.

Inventiva Cash And Cash Equivalents Related Terms

Thank you for viewing the detailed overview of Inventiva's Cash And Cash Equivalents provided by GuruFocus.com. Please click on the following links to see related term pages.

Inventiva (Inventiva) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Inventiva SA (NAS:IVA) » Definitions » Cash And Cash Equivalents
Comparable Companies
XPAR:AELIS XPAR:IPH XPAR:DBV XPAR:MEDCL XPAR:NANO XPAR:GNFT XPAR:TNG XPAR:ALSEN XPAR:ADOC XPAR:OSE OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA HKSE:02269 XBRU:ARGX BNTX
Traded in Other Exchanges
IVA:France 6IV:Germany
Address
50 rue de Dijon, Daix, FRA, 21121
Website
https://www.inventivapharma.com
Inventiva SA is a France-based biopharmaceutical company specialized in developing drugs that impact on nuclear receptors, transcription factors and epigenetic modulation. The company is focused on developing its product candidate, lanifibranor, for the treatment of patients with non-alcoholic steatohepatitis, or NASH, a disease for which there are currently no approved therapies. The company is also involved in developing a portfolio of pre-clinical therapy programs. It operates in the segment of Service delivery and clinical stage research, notably into therapies in the areas of oncology, fibrosis, and rare diseases. All the company's operations are in France. Most of the group's revenue is derived from its research partnerships with AbbVie and BI.